Oxaliplatin -- A 10-Year Trajectory

Shingo Kanaji, Eiji Oki, Hiroshi Saeki, Hiroyuki Kitao, Yoshihiko Maehara, Yoshihiro Kakeji

Research output: Contribution to journalArticle

Abstract

Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

Original languageEnglish
Pages (from-to)715-722
Number of pages8
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume43
Issue number6
Publication statusPublished - Jun 1 2016
Externally publishedYes

Fingerprint

oxaliplatin
antineoplaston A10
Platinum
Japan
Clinical Trials
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kanaji, S., Oki, E., Saeki, H., Kitao, H., Maehara, Y., & Kakeji, Y. (2016). Oxaliplatin -- A 10-Year Trajectory. Gan to kagaku ryoho. Cancer & chemotherapy, 43(6), 715-722.

Oxaliplatin -- A 10-Year Trajectory. / Kanaji, Shingo; Oki, Eiji; Saeki, Hiroshi; Kitao, Hiroyuki; Maehara, Yoshihiko; Kakeji, Yoshihiro.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 43, No. 6, 01.06.2016, p. 715-722.

Research output: Contribution to journalArticle

Kanaji, S, Oki, E, Saeki, H, Kitao, H, Maehara, Y & Kakeji, Y 2016, 'Oxaliplatin -- A 10-Year Trajectory', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 43, no. 6, pp. 715-722.
Kanaji S, Oki E, Saeki H, Kitao H, Maehara Y, Kakeji Y. Oxaliplatin -- A 10-Year Trajectory. Gan to kagaku ryoho. Cancer & chemotherapy. 2016 Jun 1;43(6):715-722.
Kanaji, Shingo ; Oki, Eiji ; Saeki, Hiroshi ; Kitao, Hiroyuki ; Maehara, Yoshihiko ; Kakeji, Yoshihiro. / Oxaliplatin -- A 10-Year Trajectory. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2016 ; Vol. 43, No. 6. pp. 715-722.
@article{b27eee18f7d24f29976ecb03a9eae02b,
title = "Oxaliplatin -- A 10-Year Trajectory",
abstract = "Oxaliplatin(Elplat({\circledR})iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.",
author = "Shingo Kanaji and Eiji Oki and Hiroshi Saeki and Hiroyuki Kitao and Yoshihiko Maehara and Yoshihiro Kakeji",
year = "2016",
month = "6",
day = "1",
language = "English",
volume = "43",
pages = "715--722",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Oxaliplatin -- A 10-Year Trajectory

AU - Kanaji, Shingo

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Kitao, Hiroyuki

AU - Maehara, Yoshihiko

AU - Kakeji, Yoshihiro

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

AB - Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.

UR - http://www.scopus.com/inward/record.url?scp=84982787182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982787182&partnerID=8YFLogxK

M3 - Article

C2 - 27306807

VL - 43

SP - 715

EP - 722

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -